Literature DB >> 29364490

Intranasal drug administration for procedural sedation in children admitted to pediatric Emergency Room.

C Fantacci1, G C Fabrizio, P Ferrara, F Franceschi, A Chiaretti.   

Abstract

OBJECTIVE: Pain relief is a very important aspect in Pediatrician's clinical practice. It is often thought that young children, particularly infants, do not perceive as much pain as adults because of their immature nervous system and that untreated pain would not have adverse long-term consequences. Instead, it has been demonstrated that infants and children experience pain in a similar manner to adults. Many factors, particularly emotional factors, can increase the child's pain perception. Children live with anxiety even minor procedures. This suggests the need for an adequate sedation and the way of sedation should be free of pain itself. We believe the route to be followed may be the intranasal (IN) administration of sedative drugs.
MATERIALS AND METHODS: We have conducted a brief review of the literature by Pubmed about the most commonly used sedative drugs: sufentanyl, fentanyl, midazolam, ketamine, nitrous oxide and dexmedetomidine. We have investigated in the literature the type of administration of IN drugs: drop instillation or by a mucosal atomizer device (MAD).
RESULTS: In our study, it was noted that IN drugs administration is an effective and safe method to reduce anxiety and to deliver analgesia because it is practical and non-invasive. Moreover, therapeutic levels of sedatives are low due to the presence of a rich vascular plexus in the nasal cavity, which communicates with the subarachnoid space via the olfactory nerve and reduce the time of medication delivery, that is, the onset of action. The use of MAD even gives as better bioavailability of drugs.
CONCLUSIONS: IN sedation via MAD is effective and safe and should be one of the first choices for procedural sedation in children.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29364490     DOI: 10.26355/eurrev_201801_14120

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

Review 1.  Evaluation of Intranasal Midazolam for Pediatric Sedation during the Suturing of Traumatic Lacerations: A Systematic Review.

Authors:  Francisco Javier Gómez-Manzano; José Alberto Laredo-Aguilera; Ana Isabel Cobo-Cuenca; Joseba Rabanales-Sotos; Sergio Rodríguez-Cañamero; Noelia Martín-Espinosa; Juan Manuel Carmona-Torres
Journal:  Children (Basel)       Date:  2022-04-29

Review 2.  Intranasal drug delivery for treatment of Alzheimer's disease.

Authors:  Leonor C Fonseca; João A Lopes; João Vieira; Cláudia Viegas; Cláudia S Oliveira; Rafael P Hartmann; Pedro Fonte
Journal:  Drug Deliv Transl Res       Date:  2021-02-26       Impact factor: 4.617

3.  Maximum volume of nasal administration using a mucosal atomization device without aspiration in Japanese White rabbits.

Authors:  Yixian Wei; Ai Hori; I-Ying Chen; Haruka Tamogi; Taku Hirokawa; Keiko Kato; Takaharu Itami; Tadashi Sano; Kazuto Yamashita
Journal:  J Vet Med Sci       Date:  2022-04-11       Impact factor: 1.105

4.  Pharmacokinetics and pharmacodynamics of intranasal remimazolam-a randomized controlled clinical trial.

Authors:  Marija Pesic; Frank Schippers; Rob Saunders; Lyn Webster; Martin Donsbach; Thomas Stoehr
Journal:  Eur J Clin Pharmacol       Date:  2020-09-04       Impact factor: 2.953

5.  Efficacy of intranasal ketamine and midazolam for pediatric sedation: A double-blind, randomized clinical trial.

Authors:  Hossein Khoshrang; Cyrus Emir Alavi; Siamak Rimaz; Ali Mirmansouri; Farnoush Farzi; Gelareh Biazar; Zahra Atrkarroushan; Nazanin Sabet Khadem
Journal:  Caspian J Intern Med       Date:  2021

6.  A Comparison of Intranasal Dexmedetomidine, Esketamine or a Dexmedetomidine-Esketamine Combination for Induction of Anaesthesia in Children: A Randomized Controlled Double-Blind Trial.

Authors:  Xinlei Lu; Ling Tang; Haiyan Lan; Chunli Li; Han Lin
Journal:  Front Pharmacol       Date:  2022-01-27       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.